A phase I study suggests that ivosidenib can induce remission in patients with 
relapsed or refractory acute myeloid leukemia characterized by IDH1 mutations. 
The drug spurred complete remission or complete remission with partial 
hematologic recovery in 30.4% of patients. The most common side effects of at 
least grade 3 were prolonged QT interval and IDH differentiation syndrome.